Raquel Samões
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raquel Samões has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Ana Martins da Silva
Porto University Hospital Center
4 shared publications - Ana Paula Sousa
Department of Neurophysiology, Hospital de Santo António, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal
4 shared publications - Ernestina Santos
Unit for Multidisciplinary Research in Biomedicine (UMIB), Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal; Department of Neurology, Centro Hospitalar do Porto-Hospital de Santo António (CHP-HSA), Porto, Portugal
3 shared publications - Manuel Melo Pires
Neuropathology Unit, Centro Hospitalar do Porto, Porto, Portugal
3 shared publications - Ricardo Taipa
Neuropathology Unit, Centro Hospitalar do Porto, Porto, Portugal
3 shared publications - Bárbara Leal
Unit for Multidisciplinary Research in Biomedicine Abel Salazar Biomedical Sciences Institute–University of Porto Porto Portugal
2 shared publications
Latest Publications
- 16 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 177, 110936
Influence of epilepsy syndrome on cancer comorbidity
- 16 February 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 177, 110936
Influence of epilepsy syndrome on cancer comorbidity
- Open Access
Motives and predictors of modified Atkins diet discontinuation as treatment of adults with drug‐resistant epilepsy
Objective: This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug‐resistant epilepsy (DRE). Methods: A single‐center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary outpatient clinic dedicated to adult patients. Time to MAD discontinuation analyses were used to explore sociodemographic, clinical, and biochemical predictors of MAD persistence. Results: Eighty patients initiated MAD (54% females, median age = 29 years, median epilepsy duration = 21 years, median baseline seizure frequency = 30/month, median antiseizure medications = 4, 68% focal epilepsy, 64% structural etiology, and 26% genetic cause). The patients used the diet for a median time of 122 days. Fifteen percent of patients were very early dropouts (before 30 days), 20% were early dropouts (30–89 days), and 17.5% were late dropouts (>365 days). The motives for dropout ( n = 64) were noncompliance (34.4%), inefficacy (23.4%), side effects (23.4%), and diet tiredness (18.8%). Female sex (adjusted hazard ratio [HR] = 1.75, p = .042), focal seizures with preserved consciousness (adjusted HR = 2.69, p = .017), higher glycemic level at baseline (adjusted HR = 1.03, p = .044), and lower level of serum total proteins at baseline (adjusted HR = .55, p = .052) were associated with shorter persistence on MAD. The HR for discontinuation was also higher for patients without daily seizures (HR = 1.72, p = .038). Among patients with at least 3 months in MAD ( n = 51), reduced clinical response at month 3 was associated with earlier discontinuation of MAD, as measured by lower percent seizure reduction (HR = .98, p = .004) and p = .027). Significance: The dropout rate of MAD in adults with DRE is high even at dedicated centers. Females, patients with less severe epilepsies, and patients previously on carbohydrate‐based diets may be more prone to earlier dropouts. These patients require closer monitoring in specialized ketogenic diet clinics to prevent MAD discontinuation before the minimum period necessary to evaluate response.
Open AccessMotives and predictors of modified Atkins diet discontinuation as treatment of adults with drug‐resistant epilepsy
Objective: This study was undertaken to explore the motives and predictors of modified Atkins diet (MAD) discontinuation as a treatment of adults with drug‐resistant epilepsy (DRE). Methods: A single‐center observational longitudinal study was made of a cohort of patients treated with MAD during the first 6 years at a multidisciplinary outpatient clinic dedicated to adult patients. Time to MAD discontinuation analyses were used to explore sociodemographic, clinical, and biochemical predictors of MAD persistence. Results: Eighty patients initiated MAD (54% females, median age = 29 years, median epilepsy duration = 21 years, median baseline seizure frequency = 30/month, median antiseizure medications = 4, 68% focal epilepsy, 64% structural etiology, and 26% genetic cause). The patients used the diet for a median time of 122 days. Fifteen percent of patients were very early dropouts (before 30 days), 20% were early dropouts (30–89 days), and 17.5% were late dropouts (>365 days). The motives for dropout ( n = 64) were noncompliance (34.4%), inefficacy (23.4%), side effects (23.4%), and diet tiredness (18.8%). Female sex (adjusted hazard ratio [HR] = 1.75, p = .042), focal seizures with preserved consciousness (adjusted HR = 2.69, p = .017), higher glycemic level at baseline (adjusted HR = 1.03, p = .044), and lower level of serum total proteins at baseline (adjusted HR = .55, p = .052) were associated with shorter persistence on MAD. The HR for discontinuation was also higher for patients without daily seizures (HR = 1.72, p = .038). Among patients with at least 3 months in MAD ( n = 51), reduced clinical response at month 3 was associated with earlier discontinuation of MAD, as measured by lower percent seizure reduction (HR = .98, p = .004) and p = .027). Significance: The dropout rate of MAD in adults with DRE is high even at dedicated centers. Females, patients with less severe epilepsies, and patients previously on carbohydrate‐based diets may be more prone to earlier dropouts. These patients require closer monitoring in specialized ketogenic diet clinics to prevent MAD discontinuation before the minimum period necessary to evaluate response.
- Open Access
Characterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers
Introduction: Anti-GAD65 antibodies are associated with several neurological phenotypes. Antibody titers are increasingly recognized as useful in diagnosis and prognosis. Objective: To describe a Portuguese cohort of patients with anti-GAD65-associated neurological syndromes. Methods: Retrospective analysis of all patients with positive anti-GAD65 antibodies and associated neurological syndromes followed in a tertiary referral center. Results: Nineteen anti-GAD65 antibody-positive neurological patients were identified, 62.3% female, with a mean age of onset of 56.0 (SD = 13.3) years. Comorbid autoimmune disorders were present in seven patients. Six patients had limbic encephalitis (31.6%), four had epilepsy (21.1%), four had cerebellar ataxia (21.1%), and three had stiff-person syndrome (15.8%). Two patients presented with isolated cognitive dysfunction (executive and mnesic) in the absence of other neurological symptoms. The mean follow-up time was 24.0 (14.0–42.0) months, at the end of which the mean modified Rankin Scale (mRS) value was 2.0 (1.0–4.0). Screening for malignancies was negative in all patients. Serum quantitative analysis was carried out in 18 patients, 10 of whom showed titers above previously defined cut-off points (>10,000 IU/L for ELISA and >20 mmol/L for RIA). Quantitative CSF analysis was performed in nine patients, with four showing above-threshold titers. There was no association between anti-GAD65 levels and clinical phenotype or the final mRS values. High-dose intravenous methylprednisolone and oral prednisolone were the most common acute and chronic treatment regimens, respectively. Conclusion: Anti-GAD65 antibodies are associated with varied neurological syndromes, and antibody titers alone should not be used to exclude a disease.
Open AccessCharacterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers
Introduction: Anti-GAD65 antibodies are associated with several neurological phenotypes. Antibody titers are increasingly recognized as useful in diagnosis and prognosis. Objective: To describe a Portuguese cohort of patients with anti-GAD65-associated neurological syndromes. Methods: Retrospective analysis of all patients with positive anti-GAD65 antibodies and associated neurological syndromes followed in a tertiary referral center. Results: Nineteen anti-GAD65 antibody-positive neurological patients were identified, 62.3% female, with a mean age of onset of 56.0 (SD = 13.3) years. Comorbid autoimmune disorders were present in seven patients. Six patients had limbic encephalitis (31.6%), four had epilepsy (21.1%), four had cerebellar ataxia (21.1%), and three had stiff-person syndrome (15.8%). Two patients presented with isolated cognitive dysfunction (executive and mnesic) in the absence of other neurological symptoms. The mean follow-up time was 24.0 (14.0–42.0) months, at the end of which the mean modified Rankin Scale (mRS) value was 2.0 (1.0–4.0). Screening for malignancies was negative in all patients. Serum quantitative analysis was carried out in 18 patients, 10 of whom showed titers above previously defined cut-off points (>10,000 IU/L for ELISA and >20 mmol/L for RIA). Quantitative CSF analysis was performed in nine patients, with four showing above-threshold titers. There was no association between anti-GAD65 levels and clinical phenotype or the final mRS values. High-dose intravenous methylprednisolone and oral prednisolone were the most common acute and chronic treatment regimens, respectively. Conclusion: Anti-GAD65 antibodies are associated with varied neurological syndromes, and antibody titers alone should not be used to exclude a disease.
- 13 June 2024
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 45 (7) , 977-986
MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis: A Systematic Review and Meta-analysis
BACKGROUND: Antibodies against leucine-rich glioma inactivated protein 1 (LGI1) constitute a common form of autoimmune encephalitis. On MR imaging, it may show T2 FLAIR hyperintensities of the medial temporal lobe (T2 FLAIR-MTL), involve the basal ganglia, or be unremarkable. PURPOSE: We performed a systematic review and meta-analysis to obtain prevalence estimates of abnormal findings on MR imaging in anti-LGI1 encephalitis. A human brain map of the LGI1 microarray gene expression was derived from the Allen Human Brain Atlas. DATA SOURCES: PubMed and Web of Science were searched with the terms “LGI1” and “encephalitis” from inception to April 7, 2022. STUDY SELECTION: Thirty-one research publications, encompassing case series and retrospective cohort and case-control studies, with >10 patients with anti-LGI1 encephalitis and MR imaging data were included. DATA ANALYSIS: Pooled prevalence estimates were calculated using Freeman-Tukey double-arcsine transformation. Meta-analysis used DerSimonian and Laird random effects models. DATA SYNTHESIS: Of 1318 patients in 30 studies, T2 FLAIR-MTL hyperintensities were present in 54% (95% CI, 0.48–0.60; I2 = 76%). Of 394 patients in 13 studies, 27% showed bilateral (95% CI, 0.19–0.36; I2 = 71%) and 24% unilateral T2 FLAIR-MTL abnormalities (95% CI, 0.17–0.32; I2 = 61%). Of 612 patients in 15 studies, basal ganglia abnormalities were present in 10% (95% CI, 0.06–0.15; I2 = 67%). LGI1 expression was highest in the amygdala, hippocampus, and caudate nucleus. LIMITATIONS: Only part of the spectrum of MR imaging abnormalities in anti-LGI1 encephalitis could be included in a meta-analysis. MR imaging findings were not the main outcomes in most studies, limiting available information. I2 values ranged from 62% to 76%, representing moderate-to-large heterogeneity. CONCLUSIONS: T2 FLAIR-MTL hyperintensities were present in around one-half of patients with anti-LGI1. The prevalence of unilateral and bilateral presentations was similar, suggesting unilaterality should raise the suspicion of this disease in the appropriate clinical context. Around 10% of patients showed basal ganglia abnormalities, indicating that special attention should be given to this region. LGI1 regional expression coincided with the most frequently reported abnormal findings on MR imaging. Regional specificity might be partially determined by expression levels of the target protein.
- 13 June 2024
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 45 (7) , 977-986
MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis: A Systematic Review and Meta-analysis
BACKGROUND: Antibodies against leucine-rich glioma inactivated protein 1 (LGI1) constitute a common form of autoimmune encephalitis. On MR imaging, it may show T2 FLAIR hyperintensities of the medial temporal lobe (T2 FLAIR-MTL), involve the basal ganglia, or be unremarkable. PURPOSE: We performed a systematic review and meta-analysis to obtain prevalence estimates of abnormal findings on MR imaging in anti-LGI1 encephalitis. A human brain map of the LGI1 microarray gene expression was derived from the Allen Human Brain Atlas. DATA SOURCES: PubMed and Web of Science were searched with the terms “LGI1” and “encephalitis” from inception to April 7, 2022. STUDY SELECTION: Thirty-one research publications, encompassing case series and retrospective cohort and case-control studies, with >10 patients with anti-LGI1 encephalitis and MR imaging data were included. DATA ANALYSIS: Pooled prevalence estimates were calculated using Freeman-Tukey double-arcsine transformation. Meta-analysis used DerSimonian and Laird random effects models. DATA SYNTHESIS: Of 1318 patients in 30 studies, T2 FLAIR-MTL hyperintensities were present in 54% (95% CI, 0.48–0.60; I2 = 76%). Of 394 patients in 13 studies, 27% showed bilateral (95% CI, 0.19–0.36; I2 = 71%) and 24% unilateral T2 FLAIR-MTL abnormalities (95% CI, 0.17–0.32; I2 = 61%). Of 612 patients in 15 studies, basal ganglia abnormalities were present in 10% (95% CI, 0.06–0.15; I2 = 67%). LGI1 expression was highest in the amygdala, hippocampus, and caudate nucleus. LIMITATIONS: Only part of the spectrum of MR imaging abnormalities in anti-LGI1 encephalitis could be included in a meta-analysis. MR imaging findings were not the main outcomes in most studies, limiting available information. I2 values ranged from 62% to 76%, representing moderate-to-large heterogeneity. CONCLUSIONS: T2 FLAIR-MTL hyperintensities were present in around one-half of patients with anti-LGI1. The prevalence of unilateral and bilateral presentations was similar, suggesting unilaterality should raise the suspicion of this disease in the appropriate clinical context. Around 10% of patients showed basal ganglia abnormalities, indicating that special attention should be given to this region. LGI1 regional expression coincided with the most frequently reported abnormal findings on MR imaging. Regional specificity might be partially determined by expression levels of the target protein.
- 6 October 2023
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (3) , 169-171
Neurological manifestations of rheumatoid arthritis – Nearly 50 years of experience
- 6 October 2023
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (3) , 169-171
Neurological manifestations of rheumatoid arthritis – Nearly 50 years of experience
- 29 September 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 234, 107994
Distinct phenotypes in a cohort of anti-CASPR2 associated neurological syndromes
- 29 September 2023
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 234, 107994
Distinct phenotypes in a cohort of anti-CASPR2 associated neurological syndromes
- 1 July 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 52, 102982
Depression and anxiety in multiple sclerosis patients: The role of genetic variability of interleukin 1β
- 1 July 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 52, 102982
Depression and anxiety in multiple sclerosis patients: The role of genetic variability of interleukin 1β
- Open Access
- 24 May 2021
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 75 (8) , 269-270
Persistently positive anti‐NMDA receptor antibodies in chronic psychotic disorder: foe or innocent bystander?
- 24 May 2021
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 75 (8) , 269-270
Open AccessPersistently positive anti‐NMDA receptor antibodies in chronic psychotic disorder: foe or innocent bystander?
- 3 April 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (2) , 73-77
Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome
Introduction: Carpal tunnel syndrome (CTS) is a nonspecific manifestation of hereditary ATTR amyloidosis (ATTRm). Amyloid deposition of wild-type TTR (WT-ATTR) has been found in transverse carpal ligament (TCL) in idiopathic CTS. We retrospectively studied a group of patients with ATTRm and CTS submitted to carpal tunnel release surgery (CTRS). Methods: From the nerve conduction studies performed in our Clinical Unit dedicated to hereditary amyloidosis between July 2009 and October 2013, we selected patients who fulfilled neurophysiological criteria for CTS, had been submitted to CTRS and whose TCL was available for pathology. Clinical registries were reviewed and amyloid detection in the ligaments was performed using Congo-red staining. Results: We included 16 patients: three males (18.8%), mean age = 46.1 years old, all with V30M mutation. At the time of surgery, four patients were considered asymptomatic and 12 symptomatic carriers, five of them late-onset ATTRm (onset age >50 years old). In all but one patient, the CTS preceded the polyneuropathy. Amyloid detection in the TCL was positive in 14 patients (87.5%). Discussion/conclusions: In most patients, CTS preceded or was contemporary to the polyneuropathy and amyloid detection in TCL was positive. The detection of amyloid in TCL may add specificity to CTS as an early manifestation of the disease but more studies are needed.
- 3 April 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (2) , 73-77
Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome
Introduction: Carpal tunnel syndrome (CTS) is a nonspecific manifestation of hereditary ATTR amyloidosis (ATTRm). Amyloid deposition of wild-type TTR (WT-ATTR) has been found in transverse carpal ligament (TCL) in idiopathic CTS. We retrospectively studied a group of patients with ATTRm and CTS submitted to carpal tunnel release surgery (CTRS). Methods: From the nerve conduction studies performed in our Clinical Unit dedicated to hereditary amyloidosis between July 2009 and October 2013, we selected patients who fulfilled neurophysiological criteria for CTS, had been submitted to CTRS and whose TCL was available for pathology. Clinical registries were reviewed and amyloid detection in the ligaments was performed using Congo-red staining. Results: We included 16 patients: three males (18.8%), mean age = 46.1 years old, all with V30M mutation. At the time of surgery, four patients were considered asymptomatic and 12 symptomatic carriers, five of them late-onset ATTRm (onset age >50 years old). In all but one patient, the CTS preceded the polyneuropathy. Amyloid detection in the TCL was positive in 14 patients (87.5%). Discussion/conclusions: In most patients, CTS preceded or was contemporary to the polyneuropathy and amyloid detection in TCL was positive. The detection of amyloid in TCL may add specificity to CTS as an early manifestation of the disease but more studies are needed.
- 28 February 2017
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 4 (1) , 67-76
RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre
Background: Pathogenic variants in ryanodine receptor type 1 (RYR1 ) gene are an important cause of congenital myopathy. The clinical, histopathologic and genetic spectrum is wide. Objective: Review a group of the patients diagnosed with ryanodinopat
- 28 February 2017
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 4 (1) , 67-76
RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre
Background: Pathogenic variants in ryanodine receptor type 1 (RYR1 ) gene are an important cause of congenital myopathy. The clinical, histopathologic and genetic spectrum is wide. Objective: Review a group of the patients diagnosed with ryanodinopat